Celltrion Healthcare Co., Ltd.

KOSDAQ:A091990 Stock Report

Market Cap: ₩11.9t

Celltrion Healthcare Valuation

Is A091990 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A091990 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A091990 (₩75900) is trading above our estimate of fair value (₩14102.78)

Significantly Below Fair Value: A091990 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A091990?

Key metric: As A091990 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A091990. This is calculated by dividing A091990's market cap by their current revenue.
What is A091990's PS Ratio?
PS Ratio5.4x
Sales₩2.22t
Market Cap₩11.91t

Price to Sales Ratio vs Peers

How does A091990's PS Ratio compare to its peers?

The above table shows the PS ratio for A091990 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.8x
A008930 Hanmi Science
1.6xn/a₩2.0t
A067630 HLB Life Science
12.2xn/a₩1.2t
A032940 Wonik
0.4xn/a₩61.6b
A299170 WSI
1xn/a₩38.2b
A091990 Celltrion Healthcare
5.4x17.2%₩11.9t

Price-To-Sales vs Peers: A091990 is expensive based on its Price-To-Sales Ratio (5.4x) compared to the peer average (4.4x).

Price to Sales Ratio vs Industry

How does A091990's PS Ratio compare vs other companies in the Asian Healthcare Industry?

62 CompaniesPrice / SalesEstimated GrowthMarket Cap
A091990 5.4xIndustry Avg. 1.7xNo. of Companies63PS01.63.24.86.48+
62 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A091990 is expensive based on its Price-To-Sales Ratio (5.4x) compared to the Asian Healthcare industry average (1.8x).

Price to Sales Ratio vs Fair Ratio

What is A091990's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A091990 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.4x
Fair PS Ratio3.1x

Price-To-Sales vs Fair Ratio: A091990 is expensive based on its Price-To-Sales Ratio (5.4x) compared to the estimated Fair Price-To-Sales Ratio (3.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A091990 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
Dec ’25n/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
Nov ’25n/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
Oct ’25n/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
Sep ’25n/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
Aug ’25n/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
Jul ’25n/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
Jun ’25n/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
May ’25n/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
Apr ’25n/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
Mar ’25n/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
Feb ’25n/a
₩89,111.11
0%
4.0%₩95,000.00₩85,000.00n/a9
Jan ’25n/a
₩90,100.00
0%
5.0%₩99,000.00₩85,000.00n/a10
Dec ’24₩72,100.00
₩90,166.67
+25.1%
4.5%₩99,000.00₩85,000.00n/a12
Nov ’24₩66,900.00
₩89,636.36
+34.0%
3.8%₩95,000.00₩85,000.00n/a11
Oct ’24₩63,000.00
₩85,833.33
+36.2%
15.2%₩95,000.00₩44,000.00n/a12
Sep ’24₩64,700.00
₩85,153.85
+31.6%
15.0%₩95,000.00₩44,000.00n/a13
Aug ’24₩66,600.00
₩84,166.67
+26.4%
16.0%₩94,000.00₩44,000.00n/a12
Jul ’24₩65,500.00
₩84,416.67
+28.9%
15.9%₩93,000.00₩44,000.00n/a12
Jun ’24₩76,700.00
₩84,416.67
+10.1%
15.9%₩93,000.00₩44,000.00n/a12
May ’24₩69,400.00
₩82,003.50
+18.2%
16.9%₩93,000.00₩44,000.00n/a11
Apr ’24₩60,200.00
₩77,676.92
+29.0%
17.3%₩93,000.00₩44,000.00n/a10
Mar ’24₩54,500.00
₩83,332.22
+52.9%
19.1%₩109,000.00₩47,116.00n/a11
Feb ’24₩60,300.00
₩85,101.45
+41.1%
18.5%₩109,000.00₩47,116.00n/a11
Jan ’24₩58,000.00
₩84,090.90
+45.0%
17.9%₩104,807.69₩47,115.38n/a11
Dec ’23₩63,173.08
₩84,090.91
+33.1%
17.9%₩104,807.69₩47,115.38₩72,100.0011

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/12 13:09
End of Day Share Price 2024/01/12 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Celltrion Healthcare Co., Ltd. is covered by 29 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Girish BakhruBofA Global Research
Hyung Soo KimCape Investment & Securities Co., Ltd.
Sunghwan KimCredit Suisse